Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary) ; Gallium 68 RM2 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
Most Recent Events
- 09 Jan 2024 Status changed from completed to discontinued. (Lack of accrual due to pandemic and logistics )
- 18 Sep 2023 Status changed from suspended to completed.
- 17 Jun 2022 Planned End Date changed from 31 Jul 2026 to 31 Jul 2027.